(tigerlily713, Pixabay)
29 July 2018. Among our favorite stories on Science & Enterprise are when interesting science becomes a business opportunity. Last Wednesday, we reported on Convelo Therapeutics, a spin-off enterprise from Case Western Reserve University in Cleveland, commercializing research by its two geneticist founders that stimulate stem cells to replenish damaged myelin around nerve cells in the brain. Myelin is the waxy substance protecting nerve cells that gets destroyed by multiple sclerosis. The company emerged from stealth mode when the founders published papers in two Nature journals on Wednesday.
Here are other stories we covered last week:
- Infographic – U.S. Smoking Rate Hits New Low
- Challenges Seek Solutions for Chronic Diseases, Oral Drugs in Animals
- Drug Discovery System Designed to Identify Difficult Targets
- Experimental Drug Extends Survival, Reverses Inherited ALS Damage
- BASF, UC-Davis Partner on Human Milk Sugars
- GSK, 23andMe Ink Precision Meds Discovery Deal
- Merck, Biopharma Partner on Cell-Free Immune System Therapies
- Tissue-Engineered Heart Chamber Model Developed
* * *
RSS - Posts
You must be logged in to post a comment.